Mortality in Patients With Septic Shock by Multidrug Resistant Bacteria: Risk Factors and Impact of Sepsis Treatments

Journal of Intensive Care Medicine

Volumn 34, Issue 1, 2019, Pages 48-54

  Busani, Stefano ^a   Serafini, Giulia ^a   Mantovani, Elena ^a   Venturelli, Claudia ^a   Giannella, Maddalena ^b   Viale, Pierluigi ^b   Mussini, Cristina ^c   Cossarizza, Andrea ^c   Girardis, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

host immune response; multidrug resistant bacteria; sepsis bundle treatment; septic shock

Indexed keywords

ANTIBIOTIC AGENT; DOBUTAMINE; DROTRECOGIN; HYDROCORTISONE; IMMUNOGLOBULIN M; LEVOSIMENDAN; NORADRENALIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER INFECTION; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL PROTOCOL; COMORBIDITY; COMPARATIVE STUDY; CONTINUOUS RENAL REPLACEMENT THERAPY; ENTEROBACTERIACEAE; ENTEROCOCCUS; EVIDENCE BASED MEDICINE; FEMALE; FLUID RESUSCITATION; HEART VOLUME; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MAXIMAL INSPIRATORY PRESSURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY RISK; MULTIDRUG RESISTANCE; OXYGEN SATURATION; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; HOSPITAL MORTALITY; INSURANCE; MICROBIAL SENSITIVITY TEST; MORTALITY; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREEXISTING CONDITION COVERAGE; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SHOCK, SEPTIC;

EID: 85016626279     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066616688165     Document Type: Article

References (27)

1. Gudiol C, Calatayud L, Garcia-Vidal C. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333–341
2. Lim CJ, Cheng AC, Kennon J. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. J Antimicrob Chemother. 2014;69(7):1972–1980
3. Fukuta Y, Muder RR, Agha ME. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control. 2013;41(12):1249–1252
4. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66(5):401–414
5. Zavascki AP, Barth AL, Goncalves AL. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2006;58(2):387–392
6. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect Dis. 2011;11(5):381–393
7. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596
8. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–268
9. van Vught LA, Klein Klouwenberg PM, Spitoni C. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315(14):1469–1479
10. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 2015;81(4):426–439
11. Levy MM, Fink MP, Marshall JC. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530–538
12. Sievert DM, Ricks P, Edwards JR. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14
13. Magiorakos AP, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281
14. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35(12):2677–2685
15. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35(12):2686–2692
16. Turgeon AF, Hutton B, Fergusson DA. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146(3):193–203
17. Uchino S, Bellomo R, Morimatsu H. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563–1570
18. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957–2963
19. Vincent JL, Moreno R, Takala J. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22(7):707–710
20. Zhou J, Qian C, Zhao M. Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland China. PLoS One. 2014;9(9):e107181
21. Torres VB, Azevedo LC, Silva UV. Sepsis-associated outcomes in critically ill patients with malignancies. Ann Am Thorac Soc. 2015;12(8):1185–1192
22. Namendys-Silva SA, Correa-Garcia P, Garcia-Guillen FJ. Outcomes of critically ill cancer patients with Acinetobacter baumannii infection. World J Crit Care Med. 2015;4(3):258–264
23. Garnacho-Montero J, Dimopoulos G, Poulakou G. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41(12):2057–2075
24. Giamarellos-Bourboulis EJ, Tziolos N, Routsi C. Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect. 2016;22(6):499–506
25. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther. 2013;11(10):1053–1063
26. Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. Minerva Anestesiol. 2016;82(5):559–572
27. Cavazzuti I, Serafini G, Busani S. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med. 2014;40(12):1888–1896